RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.

Expert Comments:

Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space.
read more >
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia.
read more >
Douglas Loe, Echelon Wealth Partners (9/6/18)
"Results for now are not meaningful on the topline given RepliCel Life Sciences Inc.'s status as a drug developer, but liquidity metrics in Q2/18 indicated the firm exited with cash of $48.8K, ahead of anticipated liquidity needs of $4.6M on a 12-month basis until June 2019; cash of this magnitude does not include the company's agreement with YOFOTO."

Douglas Loe, Echelon Wealth Partners (7/12/18)
"RepliCel Life Sciences Inc. formally confirmed today that it has finalized and signed on its licensing and codevelopment deal with Chinese firm YOFOTO (private). Terms of the deal were essentially similar to revised terms announced back in May 2018."

More Expert Comments

Experts Following This Company

Douglas Loe, Analyst – Echelon Wealth Partners
Colin Lee Novick, Managing Director – CJ PARTNERS

The information provided above is from analysts, newsletters, the company and other contributors.

RepliCel Life Sciences Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Biotech company focused on large aesthetic and sports injury markets
Small-cap biotech company expected to be generating revenue in 2018